Daily Stock Analysis, BLUE, bluebird bio Inc, priceseries

bluebird bio Inc. Daily Stock Analysis
Stock Information
Open
133.92
Close
132.65
High
135.41
Low
132.26
Previous Close
133.98
Daily Price Gain
-1.33
YTD High
163.43
YTD High Date
Apr 3, 2019
YTD Low
95.67
YTD Low Date
Jan 2, 2019
YTD Price Change
33.15
YTD Gain
33.32%
52 Week High
183.00
52 Week High Date
Jul 13, 2018
52 Week Low
87.49
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-47.95
52 Week Gain
-26.55%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 23. 2017
78.30
Mar 6. 2017
84.21
7 Trading Days
7.55%
Link
LONG
Jun 2. 2017
84.15
Jun 23. 2017
109.58
15 Trading Days
30.22%
Link
LONG
Aug 22. 2017
95.45
Sep 21. 2017
128.60
21 Trading Days
34.73%
Link
LONG
Dec 7. 2017
167.90
Dec 22. 2017
176.52
11 Trading Days
5.13%
Link
LONG
Jan 17. 2018
175.25
Feb 2. 2018
199.49
12 Trading Days
13.83%
Link
LONG
Mar 2. 2018
206.10
Mar 14. 2018
216.75
8 Trading Days
5.17%
Link
Company Information
Stock Symbol
BLUE
Exchange
NasdaqGS
Company URL
http://www.bluebirdbio.com
Company Phone
339-499-9300
CEO
Nick Leschly
Headquarters
Massachusetts
Business Address
60 BINNEY STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001293971
About

bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The company's lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.